Doctor Shaun Goodman
St. Michael's Hospital, Toronto (Canada)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial
Event: ESC Congress 2022
Topic: Pharmacotherapy
Session: Lipid-lowering therapy and the atheroma
PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.
Event: ESC Congress 2020
Topic: Prevention
Session: PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients
Low-density lipoprotein cholesterol goal attainment and treatment patterns in a cohort of >143,000 patients with atherosclerotic cardiovascular disease in Ontario, Canada
Event: ESC Congress 2020
Topic: Treatment
Session: Coronary Artery Disease (Chronic) ePosters
Clinical implications for post-ACS patients
Event: ESC Congress 2018
Topic: Treatment
Session: Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
Event: ESC Congress 2016
Topic: Thrombosis and platelets
Session: Dual antiplatelet therapy: the long and the short of it!
How might PCSK9 inhibition change this debate?
Event: ESC CONGRESS 2014
Topic: Primary cardiovascular prevention: interventions and outcomes
Session: New frontiers in cholesterol management in high cardiovascular risk patients
ESC 365 is supported by
